Full Press Release Details
ADMA Biologics Announces Closing of $51.75
Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
RAMSEY, N.J. and BOCA RATON, FL., May 21, 2019 - ADMA
Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company") a vertically integrated commercial
biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived
biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the
closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public
offering price of $4.00 per share, including 1,687,500 shares of Common Stock issued upon the exercise in full of the
underwriters' option to purchase additional shares. The gross proceeds from the offering are $51.75 million, before
deducting underwriting discounts and commissions and other offering expenses payable by the Company.
ADMA intends to use the net proceeds from this offering (i)
to support the commercial launch of ASCENIV anticipated during the second half of 2019, (ii) for the commercial relaunch
of BIVIGAM , (iii) to expand the manufacturing capacity of the Company's Boca Raton, FL facility, (iv) for the procurement
of raw materials for the manufacturing of ASCENIV and BIVIGAM , (v) to expand the Company's plasma collection
facility network, and (vi) for general corporate purposes and other capital expenditures.
Jefferies LLC and Raymond James & Associates, Inc. acted
as joint book-running managers for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering.
The securities described above were offered by the Company pursuant
to a "shelf" registration statement on Form S-3 (File No. 333-225048) previously filed with and declared effective
by the Securities and Exchange Commission ("SEC") on May 31, 2018. A final prospectus supplement and an accompanying
prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying
prospectus relating to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by e-mail at Prospectus_Department@Jefferies.com;
or from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, FL 33716, or by
telephone at (800) 248-8863, or by e-mail at prospectus@raymondjames.com; or by accessing the SEC's website at www.sec.gov.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a vertically integrated biopharmaceutical manufacturer with three FDA approved commercial specialty plasma-based
biologics. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.
The target patient populations include immune compromised individuals who suffer from an underlying immune deficiency disease,
or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793
and 10,259,865 related to certain aspects of its products and product candidates.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements"
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we",
"our" or the "Company"). Forward-looking statements include, without limitation, any statement that
may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate,"
"project," "intend," "forecast," "target," "anticipate," "plan,"
"planning," "expect," "believe," "will," "is likely," "will likely,"
"should," "could," "would," "may," or, in each case, their negative, or words or expressions
of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our anticipated
use of net proceeds from the public offering and our plans to develop and commercialize plasma-derived, human immune globulins
targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune
compromised patient populations. Actual events or results may differ materially from those described in this document due
to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance
that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties
inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation
or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if
at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking
statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks,
uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from
any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties
described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q
and 8-K, and any amendments thereto.
Executive Vice President and Chief Financial Officer | 201-478-5552
INVESTOR RELATIONS CONTACT:
Managing Director, LifeSci Advisors, LLC | 212-915-2568